These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians. Kaunitz AM. Int J Fertil Womens Med; 1998; 43(2):73-83. PubMed ID: 9609206 [Abstract] [Full Text] [Related]
24. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Clark MK, Sowers MR, Nichols S, Levy B. Fertil Steril; 2004 Dec; 82(6):1580-6. PubMed ID: 15589863 [Abstract] [Full Text] [Related]
25. Preventing repeat teen pregnancy: postpartum depot medroxyprogesterone acetate, oral contraceptive pills, or the patch? Thurman AR, Hammond N, Brown HE, Roddy ME. J Pediatr Adolesc Gynecol; 2007 Apr; 20(2):61-5. PubMed ID: 17418388 [Abstract] [Full Text] [Related]
26. Depo provera in perspective. McGoldrick IA. P N G Med J; 1981 Dec; 24(4):274-9. PubMed ID: 6461984 [Abstract] [Full Text] [Related]
27. Incidence of galactorrhea in young women using Depot-Medroxyprogesterone Acetate. Omar HA, Zakharia RM, Kanungo S, Huff M, McClanahan K. ScientificWorldJournal; 2006 May 05; 6():538-41. PubMed ID: 16680366 [Abstract] [Full Text] [Related]
28. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. Lara-Torre E, Edwards CP, Perlman S, Hertweck SP. J Pediatr Adolesc Gynecol; 2004 Feb 05; 17(1):17-21. PubMed ID: 15010034 [Abstract] [Full Text] [Related]
29. Some effects of depo-medroxyprogesterone acetate (DMPA): observations in the nursing infant and in the long-term user. Dahlberg K. Int J Gynaecol Obstet; 1982 Feb 05; 20(1):43-8. PubMed ID: 6126406 [Abstract] [Full Text] [Related]
30. Long-acting injectable contraception with depot medroxyprogesterone acetate. Kaunitz AM. Am J Obstet Gynecol; 1994 May 05; 170(5 Pt 2):1543-9. PubMed ID: 8178904 [Abstract] [Full Text] [Related]
31. Exposure to DMPA in pregnancy may cause low birth weight. Prog Hum Reprod Res; 1992 May 05; (23):2-3. PubMed ID: 12286194 [Abstract] [Full Text] [Related]
32. Cervical cancer risk and use of depot-medroxyprogesterone acetate in Costa Rica. Oberle MW, Rosero-Bixby L, Irwin KL, Fortney JA, Lee NC, Whatley AS, Bonhomme MG. Int J Epidemiol; 1988 Dec 05; 17(4):718-23. PubMed ID: 2976059 [Abstract] [Full Text] [Related]
34. Breast cancer and depot-medroxyprogesterone acetate: a multinational study. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Lancet; 1991 Oct 05; 338(8771):833-8. PubMed ID: 1681212 [Abstract] [Full Text] [Related]
35. Use of depo-provera in teens. Khoiny FE. J Pediatr Health Care; 1996 Oct 05; 10(5):195-201. PubMed ID: 8920351 [Abstract] [Full Text] [Related]
37. Bone mineral density in women using depot medroxyprogesterone acetate (DMPA) for at least 2 years compared to a control group: a cross sectional study. Pongsatha S, Ekmahachai M, Chaovisitsaree S, Suntornlimsiri N, Morakote N. J Med Assoc Thai; 2009 Oct 05; 92(10):1263-7. PubMed ID: 19845231 [Abstract] [Full Text] [Related]
38. Facts about injectable contraception. Contracept Rep; 1994 Mar 05; 5(1):1-2. PubMed ID: 12287737 [Abstract] [Full Text] [Related]
39. Long-term contraception with Depo-Provera: a clinical evaluation. Mukherjea M, Mukherjee P, Biswas R. Int J Fertil; 1980 Mar 05; 25(2):122-6. PubMed ID: 6117526 [Abstract] [Full Text] [Related]